Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission

Retrovirology

Table 1 Patient demographic, clinical, and laboratory parameters of HIV-1 infected mother-infant pairs.

Patient	Age	Sex	CD4+ cells/mm3	Length of infection^b	Antiviral drug	Clinical evaluation^c
Mothers
B	28 yr		509	11 mo	None	Asymptomatic
D	31 yr		480	2 yr 6 mo	None	Asymptomatic
E	26 yr		395	2 yr	ZDV^d	Symptomatic AIDS
F	23 yr		692	2 yr 10 mo	None	Asymptomatic
G	23 yr		480	10 mo	None	Asymptomatic
Infants
B	4.75 mo	M	1942	4.75 mo	None	Asymptomatic, P-1A
D	28 mo	M	46	28 mo	ddC^e	Symptomatic AIDS, P-2A, B, F, failed ZDV therapy
E	34 mo	M	588	34 mo	ZDV^d	Symptomatic AIDS, P-2A
F	1 wk	M	2953	1 wk	ZDV^d	Asymptomatic, P-1A
G	24 mo	F	4379	24 mo	ZDV^d	Asymptomatic, P-1B

^b Length of infection: The closest time of infection that we could document was the first positive HIV-1 serology date or the first visit of the patient to the AIDS treatment center where all the HIV-1 positive patients were referred to as soon as an HIV-1 test was positive. As a result, these dates may not reflect the exact dates of infection.
Mother and infant samples for each pair were collected at the same time.
^c Evaluation for infants is based on CDC criteria [65]
^dZDV: Zidovudine
^eddC: Zalcitabine

ISSN: 1742-4690